Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 2
2011 1
2014 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
Multiple sclerosis: progression rate and severity in a multicenter cohort from Algeria.
Hecham N, Nouioua S, Sifi Y, Toubal N, Aissa LA, Hattab S, Batsi D, Hamimed A, Berkane F, Oudrer N, Aidi A, Abrouk S, Daoudi S, Hamri A, Assami S, Tazir M. Hecham N, et al. Mult Scler. 2014 Dec;20(14):1923-4. doi: 10.1177/1352458514543343. Epub 2014 Aug 13. Mult Scler. 2014. PMID: 25122474 No abstract available.
LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort.
Belarbi S, Hecham N, Lesage S, Kediha MI, Smail N, Benhassine T, Ysmail-Dahlouk F, Lohman E, Benhabyles B, Hamadouche T, Assami S, Brice A, Tazir M. Belarbi S, et al. Among authors: hecham n. Parkinsonism Relat Disord. 2010 Dec;16(10):676-9. doi: 10.1016/j.parkreldis.2010.09.003. Epub 2010 Oct 8. Parkinsonism Relat Disord. 2010. PMID: 20933457
Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.
Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, Bar-Shira A, Belarbi S, Hecham N, Pollak P, Ouvrard-Hernandez AM, Bardien S, Carr J, Benhassine T, Tomiyama H, Pirkevi C, Hamadouche T, Cazeneuve C, Basak AN, Hattori N, Dürr A, Tazir M, Orr-Urtreger A, Quintana-Murci L, Brice A; French Parkinson's Disease Genetics Study Group. Lesage S, et al. Among authors: hecham n. Hum Mol Genet. 2010 May 15;19(10):1998-2004. doi: 10.1093/hmg/ddq081. Epub 2010 Mar 2. Hum Mol Genet. 2010. PMID: 20197411
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium. Healy DG, et al. Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6. Lancet Neurol. 2008. PMID: 18539534 Free PMC article.
Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?
Lesage S, Belarbi S, Troiano A, Condroyer C, Hecham N, Pollak P, Lohman E, Benhassine T, Ysmail-Dahlouk F, Dürr A, Tazir M, Brice A; French Parkinson's Disease Genetics Study Group. Lesage S, et al. Among authors: hecham n. Neurology. 2008 Nov 4;71(19):1550-2. doi: 10.1212/01.wnl.0000338460.89796.06. Neurology. 2008. PMID: 18981379 No abstract available.